COVID-19 associated with increased risk of developing various autoimmune diseases and risk could be attenuated by vaccination

A recent study published in eClinicalMedicine reports that the coronavirus disease 2019 (COVID-19) can increase the risk of various autoimmune diseases; however, this risk appears to be mitigated by vaccination against COVID-19.

Study: Risk of autoimmune diseases following COVID-19 and the potential protective effect from vaccination: a population-based cohort study. Image Credit: sdecoret /


The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the virus responsible for the coronavirus disease 2019 (COVID-19), has caused over 768 million infections and 6.9 million deaths worldwide. Previous studies have reported that a diagnosis of COVID-19 increases the risk of new-onset autoimmune diseases that affect the nervous system, musculoskeletal system, and endocrine system.

Many autoantibodies, including those targeting cyclic citrullinated peptide (CCP) the nucleus, have been detected in COVID-19 patients. These autoantibodies are known biomarkers for several autoimmune diseases, including psoriasis, inflammatory arthritis, Grave's disease, and Guillain-Barré syndrome (GBS).

During SARS-CoV-2 infection, an aberrant production of pro-inflammatory cytokines, especially interleukins (ILs) and tumor necrosis factor-a (TNF-a), often occurs. These cytokines disrupt the innate and acquired immune responses, thereby leading to the induction of autoimmunity. Likewise, virus-induced cytokines can also increase the risk of autoimmune responses by activating self-reactive T-cells without antigen recognition.

COVID-19 increases risk of autoimmunity

The current observational retrospective cohort study was conducted between April 2020 and November 2022. Herein, researchers analyzed electronic health records of Hong Kong residents, COVID-19 testing results, and COVID-19 vaccination data, all of which were obtained from concerned health authorities.

Based on COVID-19 testing results, the study population was categorized into COVID-19 and non-COVID-19 groups. Appropriate statistical analyses were performed to estimate the risk of new-onset autoimmune diseases following COVID-19. Moreover, COVID-19 vaccinated participants were compared with unvaccinated participants to assess the protective efficacy of COVID-19 vaccines against autoimmune diseases.

Important observations

A total of 1,028,721 COVID-19 and 3,168,467 non-COVID-19 individuals were identified from the dataset. The most prevalent comorbidities in the study population included diabetes, cerebrovascular disease, and malignancy.

A higher incidence rate of autoimmune diseases was observed in the COVID-19 group as compared to that in the non-COVID group. The median duration between COVID-19 diagnosis and new-onset autoimmune disease varied from 41 to 246 days.

COVID-19 patients were associated with an increased risk of developing pernicious anemia, spondyloarthritis, rheumatoid arthritis and other autoimmune arthritis, psoriasis, pemphigoid, Graves' disease, anti-phospholipid antibody syndrome, immune mediated thrombocytopenia, multiple sclerosis, and vasculitis as compared to those without a history of COVID-19.   

Overall, the impact of COVID-19 on autoimmune disease risk remained the same across gender. However, a significantly higher risk of spondyloarthritis and Graves' disease was observed in male and female participants, respectively.

The highest risk of COVID-related autoimmune arthritis, pemphigoid, and anti-phospholipid antibody syndrome was observed among older adults 65 years and older. Similarly, the highest risk of spondyloarthritis, rheumatoid arthritis, psoriasis, and multiple sclerosis was observed in individuals between 41-64 years of age. Moreover, an increased risk of Graves' disease was observed in those between 18-40 years of age.   

Among severe COVID-19 patients who required hospitalization, a higher risk of transverse myelitis and inflammatory bowel diseases (IBDs) was observed. However, non-hospitalized patients did not exhibit a similar increased risk of these condition.

Regarding COVID-19 vaccination, a lower risk of developing autoimmune arthritis, pemphigoid, immune-mediated thrombocytopenia, Graves' disease, anti-phospholipid antibody syndrome, and systemic lupus erythematosus was observed among vaccinated patients as compared to unvaccinated individuals.

Considering the site of infection, an increased trend was observed in organ-specific autoimmune disease and systemic autoimmune disease.

Some studies have reported newly diagnosed autoimmune disorders such as autoimmune liver diseases, GBS, and immunoglobulin A (IgA) as potentially rare side effects of COVID-19 vaccination. Importantly, the current study findings confirm the general consensus that COVID-19 vaccination is safe and does not increase the risk of incident autoimmune disorders among vaccinated individuals within 28 days of receiving the second vaccine dose.

Study significance

SARS-CoV-2 infection was found to increase the risk of developing a wide range of autoimmune diseases; however, this risk can be reduced by two doses of COVID-19 messenger ribonucleic acid (mRNA) vaccines.

Given these findings, scientists advise physicians to consider examining the autoimmunity status in COVID-19 patients for an early diagnosis and better management of new-onset autoimmune diseases. Moreover, the study findings can be presented in public awareness campaigns to encourage vaccine uptake.

Journal reference:
Dr. Sanchari Sinha Dutta

Written by

Dr. Sanchari Sinha Dutta

Dr. Sanchari Sinha Dutta is a science communicator who believes in spreading the power of science in every corner of the world. She has a Bachelor of Science (B.Sc.) degree and a Master's of Science (M.Sc.) in biology and human physiology. Following her Master's degree, Sanchari went on to study a Ph.D. in human physiology. She has authored more than 10 original research articles, all of which have been published in world renowned international journals.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Dutta, Sanchari Sinha Dutta. (2023, August 21). COVID-19 associated with increased risk of developing various autoimmune diseases and risk could be attenuated by vaccination. News-Medical. Retrieved on December 09, 2023 from

  • MLA

    Dutta, Sanchari Sinha Dutta. "COVID-19 associated with increased risk of developing various autoimmune diseases and risk could be attenuated by vaccination". News-Medical. 09 December 2023. <>.

  • Chicago

    Dutta, Sanchari Sinha Dutta. "COVID-19 associated with increased risk of developing various autoimmune diseases and risk could be attenuated by vaccination". News-Medical. (accessed December 09, 2023).

  • Harvard

    Dutta, Sanchari Sinha Dutta. 2023. COVID-19 associated with increased risk of developing various autoimmune diseases and risk could be attenuated by vaccination. News-Medical, viewed 09 December 2023,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
XBB.1.5 vaccine booster shows promise against new Omicron variants in latest study